MD-TOPDOWN-SYSTEMS
13.4.2022 15:02:13 CEST | Business Wire | Press release
Western Provident Association (WPA), a leading not-for-profit health insurance company and Top Down Systems Corporation (Topdown), a best-of-breed Customer Communication Management, CCM, software company announced today that they will deploy the Topdown INTOUCH solution across WPA’s customer communications operations to improve customer experience, increase productivity, and reduce costs.
Organizations across industries today are challenged with managing customer communications to achieve streamlined agile content and efficient operations while maintaining data privacy. To address these needs, Topdown has developed the INTOUCH SaaS CCM solution, an innovative cloud-based approach to CCM for sharing data, content and processes across organizations that transforms communications operations.
“As a not-for-profit insurance company in a regulated environment, we have a strategic goal to treat our customers how we expect to be treated. We are constantly exploring and evolving ways to exceed our customers’ expectations. We have a hard-earned reputation for service excellence. The smart automation and flexible integration platform of the Topdown INTOUCH solution will immediately empower our customer relations team to manage content and improve our communications,” said Mike Downing, WPA’s Chief Technology Officer.
The simple, task-focused interface of INTOUCH enables non-IT resources to create CCM templates and rules-based workflows for centralized content and branding assets. INTOUCH provides enterprise-wide functionality for template consolidation and streamlined omnichannel content updates. Template development time is significantly reduced improving the speed to market and the opportunity to grow workload volume. INTOUCH provides the highest levels of data security and privacy for all stages of content whether it is stored, in-use or in-transit.
“Transforming CCM operations to a modern cloud-based platform enables enterprises to optimize efficiencies and improve communication effectiveness in a secure environment. We are delighted to work with WPA to advance their CCM strategies while reducing their dependency for IT resources. Our INTOUCH solution and team of CCM experts enable quick platform integrations and ease of use to discover immediate gains and opportunities for business expansion,” said Matt Lederer, SVP of Sales and Marketing, Topdown.
About Western Provident Association (WPA)
WPA helps their customers access the best care. With a heritage of more than 120 years, WPA looks after families, the self-employed, the professions, SME, large companies and Global Brands.
About Topdown
Topdown provides customer communication management software and services to organizations looking to provide the best possible customer experience during high-value customer journeys. For nearly 40 years, from the mainframe to the desktop and now to the cloud, Topdown has helped companies communicate more effectively and efficiently with their customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005118/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom